Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma

Fig. 5

PM inhibits osteolysis in 5TMM mouse model. a Two-dimensional plots depict the dynamic gene expression in monocytes along pseudo-time order from vehicle or PM treated 5TMM model mice. Genes with a log-transformed fold change values greater than 0.25, the minimum percentage >0.25, and adjusted p-value < 0.05 were deemed significantly upregulated or downregulated. b Two-dimensional plots show the dynamic expression of scores of gene relative to “BIOCARAT-RANKL-PATHWAY”, “GOBP-OSTEOCLAST-DEVELOPMENT”, “GOBP-OSTEOCLAST-DIFFETENTISTION”, “WP-OSTEOCLAST-SIGNALING”, and “GOBP-OSTEOCLAST-PROLIFERATION” genes sets along with pseudo-time order in monocyte/macrophage in the vehicle or PM treated samples. y axis represents GSVA scores. Pathways are selected from the GSEA results (NES > 1, NOM p value < 0.05, and FDR q value < 0.25). c GO and GSEA results for DEGs of PM treated macrophages compared to vehicle treated. d TRAP staining shows osteoclast formation exposed to PM at indicated concentrations. e, f Micro-CT images were used to assess the bone structure of the femur, and bone parameters were measured in normal C57BL/KawRij mice and 5TMM model mice treated with vehicle or PM 10 mg/kg for 4 weeks (n = 6). All data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, t test

Back to article page